Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News AnaptysBio Inc ANAB

Healthcare Biotechnology
AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics. The Company is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032... see more

Recent & Breaking News (NDAQ:ANAB)

European Commission Approves JEMPERLI (dostarlimab), the First Anti-PD-1 Therapy Approved for Recurrent or Advanced dMMR/MSI-H Endometrial Cancer in Europe

GlobeNewswire April 23, 2021

FDA Approves JEMPERLI (dostarlimab-gxly) for dMMR Endometrial Cancer

GlobeNewswire April 22, 2021

AnaptysBio Announces Appointment of Oleg Nodelman to Board of Directors

GlobeNewswire April 12, 2021

AnaptysBio Reports Imsidolimab POPLAR Phase 2 Clinical Trial in Moderate-to-Severe Palmoplantar Pustulosis (PPP) Did Not Meet Primary Endpoint

GlobeNewswire March 8, 2021

AnaptysBio Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Pipeline Updates

GlobeNewswire February 25, 2021

AnaptysBio to Present at the 39th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 7, 2021

AnaptysBio to Present at the 2020 Jefferies London Virtual Healthcare Conference

GlobeNewswire November 13, 2020

AnaptysBio Announces Third Quarter 2020 Financial Results and Provides Pipeline Updates

GlobeNewswire November 4, 2020

AnaptysBio and GlaxoSmithKline Amend Strategic Immuno-Oncology Collaboration

GlobeNewswire October 26, 2020

AnaptysBio Reports Positive Topline Data from GALLOP Phase 2 Clinical Trial of Imsidolimab in Moderate-to-Severe Generalized Pustular Psoriasis (GPP)

GlobeNewswire October 13, 2020

AnaptysBio to Present at the 2020 Cantor Global Virtual Healthcare Conference

GlobeNewswire September 11, 2020

ANAPTYSBIO ALERT: Bragar Eagel & Squire, P.C. is Investigating AnaptysBio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

GlobeNewswire September 1, 2020

Shuman Glenn & Stecker Investigates AnaptysBio, Inc.

Business Wire August 24, 2020

AnaptysBio Announces Second Quarter 2020 Financial Results and Provides Pipeline Updates

GlobeNewswire August 10, 2020

AnaptysBio Reports Top-Line Data from Interim Analysis of ECLIPSE Phase 2 Clinical Trial of Etokimab in Chronic Rhinosinusitis with Nasal Polyps

GlobeNewswire August 10, 2020

AnaptysBio to Present at The 2020 Wedbush PacGrow Healthcare Conference

GlobeNewswire August 5, 2020

AnaptysBio Appoints Dr. Paul F. Lizzul As Chief Medical Officer

GlobeNewswire July 31, 2020

AnaptysBio Expands Executive Leadership Team

GlobeNewswire July 15, 2020

AnaptysBio Announces Orphan Drug Designation of Imsidolimab For Treatment of Generalized Pustular Psoriasis

GlobeNewswire July 8, 2020

Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Contact the Firm; Should Management be Held Accountable for Investors' Losses?

PR Newswire July 2, 2020